Avenue Therapeutics (FRA:49Y) Total Stockholders Equity : €3.25 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Avenue Therapeutics Total Stockholders Equity?

Avenue Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2025 was €3.25 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Avenue Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 was €1.58. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Avenue Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.00.

Avenue Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Avenue Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avenue Therapeutics Total Stockholders Equity Chart

Avenue Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

1.94

3.05

3.69

1.45

2.67

Avenue Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															2.61	4.43	2.35	2.67	3.25

Avenue Therapeutics (FRA:49Y) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Avenue Therapeutics's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(3.247	-	0)	/	2.054
	=	1.58

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Avenue Therapeutics's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.247
	=	0.00

Avenue Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Avenue Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Avenue Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avenue Therapeutics Inc (FRA:49Y) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ATXI:USA

Address

1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154

Website

https://www.avenuetx.com

Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its current product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's Disease), intravenous tramadol (IV tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders.

Avenue Therapeutics Headlines

No Headlines